Format and content for post-market drug benefit-risk assessment in Canada. : H164-255/2019E-PDF
"The objective of this guidance document is to assist Market Authorization Holders (MAHs) in developing a post-market benefit-risk assessment for a marketed drug when requested"--Objective, page 1.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.865274&sl=1
Ministère/Organisme | Canada. Health Canada. |
---|---|
Titre | Format and content for post-market drug benefit-risk assessment in Canada. |
Type de publication | Monographie |
Langue | [Anglais] |
Format | Électronique |
Document électronique | |
Note(s) | Issued also in French under title: Format et contenu des évaluations des avantages et des risques après la mise en marché au Canada. "Guidance document." Issued also in HTML format. Includes references. |
Information sur la publication | Ottawa : Health Canada, 2019. ©2019 |
Description | 1 online resource (iii, 15 pages) |
ISBN | 9780660287041 |
Numéro de catalogue |
|
Numéro de catalogue du ministère | Pub.: 180752 |
Descripteurs | Drugs |